A Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prEvention of graft-versushost disease in patients receiving hematopoietic cell transplant MODULAATE Study

Brief Summary

Type:
Hematologic - Other

Study Type:
Treatment

Phase:
II/III

ClinicalTrials.gov Identifier:
NCT03805789

Study #:
STUDY00143706

Start Date:
Apr 03, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03805789

View Complete Trial Details & Eligibility at ClinicalTrials.gov